Trial Profile
Open, booster vaccination study to assess safety and reactogenicity of GSK Biologicals' dTpa vaccine (Boostrix) when administered to healthy Chinese children 6-8 years of age
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs DTaP vaccine (Primary)
- Indications Diphtheria; Pertussis; Tetanus
- Focus Adverse reactions; Registrational
- Sponsors GlaxoSmithKline; GSK
- 12 Jan 2007 Status change
- 11 Dec 2006 New trial record.